Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03976102
Title Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in LTB Follicular Lymphoma (FLINTER) (FLINTER)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Dr. Reddy's Laboratories Limited
Indications

follicular lymphoma

Therapies

Rituximab

DRL_RI

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.